Article ; Online: Emerging roles of cytosolic phosphoenolpyruvate kinase 1 (PCK1) in cancer.
Biochemistry and biophysics reports
2023 Volume 35, Page(s) 101528
Abstract: Although it was traditionally believed that gluconeogenesis enzymes were absent from cancers that did not originate in gluconeogenic organs, numerous investigations have shown that they are functionally expressed in a variety of tumors as mediators of ... ...
Abstract | Although it was traditionally believed that gluconeogenesis enzymes were absent from cancers that did not originate in gluconeogenic organs, numerous investigations have shown that they are functionally expressed in a variety of tumors as mediators of shortened forms of Gluconeogenesis. One of the isomers of PEPCK, the first-rate limiting enzyme in gluconeogenesis, is PCK 1, which catalyzes the conversion of oxaloacetate (OAA) and GTP into PEP, CO2, and GDP. It is also known as PEPCK-C or PCK1, and it is cytosolic. Despite being paradoxical, it has been demonstrated that, in addition to its enzymatic role in normal metabolism, this enzyme also plays a role in tumors that arise in gluconeogenic and non-gluconeogenic organs. According to newly available research, it has metabolic and non-metabolic roles in tumor progression and development. Thus, this review will give insight into |
---|---|
Language | English |
Publishing date | 2023-08-18 |
Publishing country | Netherlands |
Document type | Journal Article ; Review |
ZDB-ID | 2831046-9 |
ISSN | 2405-5808 ; 2405-5808 |
ISSN (online) | 2405-5808 |
ISSN | 2405-5808 |
DOI | 10.1016/j.bbrep.2023.101528 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.